In November, the US Food and Drug Administration authorized the use of two monoclonal antibody products, bamlanivimab (Lilly) and casirivimab/imdevimab (Regeneron), to treat outpatients with COVID-19 who are at high risk for complications or hospitalization.
The US government has allocated more than 641,000 monoclonal antibody treatments to the states in the hope of preventing hospitalizations and easing pressure on strained hospitals. However, federal officials reported in January that more than half of that reserve sits unused as clinicians grapple with best practices.
Tell us your thoughts about treating COVID-19 patients with monoclonal antibodies.
Medscape Reader Polls © 2021
Cite this: Are You Prescribing Monoclonal Antibodies for COVID-19? - Medscape - Feb 03, 2021.
Comments